Nanobiotix S.A. NBTX
We take great care to ensure that the data presented and summarized in this overview for Nanobiotix S.A. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NBTX
View all-
Johnson & Johnson New Brunswick, NJ5.62MShares$18.5 Million10.31% of portfolio
-
Perceptive Advisors LLC New York, NY555KShares$1.83 Million0.08% of portfolio
-
Black Rock Inc. New York, NY239KShares$786,3360.0% of portfolio
-
Citigroup Inc3.42KShares$11,2610.0% of portfolio
-
Ubs Group Ag3.1KShares$10,1990.0% of portfolio
-
Gamma Investing LLC Foster City, CA2.86KShares$9,3990.0% of portfolio
-
Bank Of America Corp Charlotte, NC706Shares$2,3220.0% of portfolio
-
Barclays PLC London, X0110Shares$3610.0% of portfolio
-
Rhumbline Advisers Boston, MA33Shares$1080.0% of portfolio
-
Morgan Stanley New York, NY2Shares$60.0% of portfolio
Latest Institutional Activity in NBTX
Top Purchases
Top Sells
About NBTX
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Insider Transactions at NBTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|